Evidence map›Paper›PMID 38965176›Full record

ArticleActa neurologica Belgica2024

Atypical presentations in an RTD patient and report of novel SLC52A3 and SLC52A2 mutations.

Donya Sabeghi, Kolsoum InanlooRahatloo, Hanieh S Mirzadeh, Marzieh Khani, Hosein Shamshiri, Tarannomsadat Taghavi, Afagh Alavi, Reza Boostani, Seyed Hassan Tonekaboni, Javad Akhondian and 4 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Acta neurologica Belgica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Donya SabeghiSchool of Biology, College of Science, University of Tehran, Enghelab Ave, Tehran, Iran.
Kolsoum InanlooRahatlooSchool of Biology, College of Science, University of Tehran, Enghelab Ave, Tehran, Iran. inanloo@ut.ac.ir.
Hanieh S MirzadehDepartment of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Marzieh KhaniSchool of Biology, College of Science, University of Tehran, Enghelab Ave, Tehran, Iran.
Hosein ShamshiriIranian Neuromusclar Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Tarannomsadat TaghaviSchool of Biology, College of Science, University of Tehran, Enghelab Ave, Tehran, Iran.
Afagh AlaviIranian Neuromusclar Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Reza BoostaniDepartment of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyed Hassan TonekaboniPediatric Neurology, School of Medicine, Mofid Children's Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran.
Javad AkhondianDepartment of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Masoomah EbrahimiPediatric Neurology, School of Medicine, Mofid Children's Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran.
Najmeh SalehiSchool of Biological Science, Institute for Research in Fundamental Sciences (IPM), Tehran, Iran.
Shahriar NafissiIranian Neuromusclar Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Elahe ElahiSchool of Biology, College of Science, University of Tehran, Enghelab Ave, Tehran, Iran.

Funding

Iran National Science Foundation 4005531Tehran University of Medical Sciences and Health Services IR.TUMS.VCR.REC.1397.017
6 · The paper itself

Abstract

introductionRiboflavin Transporter Deficiency (RTD) is a rare neurological disorder characterized by pontobulbar palsy, hearing loss, and motor cranial nerve involvement. SLC52A3 and SLC52A2 mutations are causes of RTD. SLC52A2 mutations are usually found in childhood onset cases. Fifteen Iranian RTD diagnosed patients without SLC52A2 mutations have been previously described. We aimed to identify causative mutations in two childhood cases.

methodsWe recruited patients with diagnosis of BVVL. Comprehensive clinical evaluations were performed on the patients. SLC52A3 and SLC52A2 genes were PCR-amplified and Sanger sequenced. Candidate disease causing variations were screened for segregation with disease status in the respective families and control individuals.

resultsA novel homozygous SLC52A3 mutation (p.Met1Val) and a heterozygous SLC52A2 mutation (p.Ala288Val) were both observed in one proband with typical RTD presentations. The aggregate of presentations in the early stages of disease in the second patient that included weakness in the lower extremities, absence of bulbar or hearing defects, prominent sensory polyneuropathy as evidenced in electrodiagnostic studies, and absence of sensory symptoms including sensory ataxia did not prompt immediate RTD diagnosis. Dysarthria and decreased hearing manifested later in the disease course. A novel homozygous SLC52A2 (p.Val314Met) mutation was identified.

conclusionA literature search found recent reports of other atypical RTD presentations. These include MRI findings, speech understanding difficulties accompanied by normal hearing, anemia, and left ventricular non-compaction. Knowledge of unusual presentations lessens the chance of misdiagnosis or delayed RTD diagnosis which, in light of favorable effects of riboflavin supplementation, is of immense importance.

Indexed as

Membrane Transport ProteinsMutationBasal Ganglia DiseasesBulbar Palsy, ProgressiveChildFemaleHearing Loss, SensorineuralHumansMalePedigreeReceptors, G-Protein-CoupledMembrane Transport ProteinsReceptors, G-Protein-CoupledSLC52A2 protein, humanSLC52A3 protein, humanAtypical presentationsBrown-Vialetto-Van Laere syndrome (BVVL)Riboflavin transporter deficiency disease (RTD)SLC52A2SLC52A3

Identifiers

PMID38965176

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.